Top Markets
Coin of the day
Acura Pharmaceuticals, Inc. Acura Pharmaceuticals, Inc.

Acura Pharmaceuticals, Inc.

ACUR
株式のランク #41976
Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to... Acura Pharmaceuticals, Inc. operates as a drug delivery innovator, dedicated to exploring, developing, and bringing to market novel technologies and products aimed at enhancing medication safety across the United States. Its product portfolio features Oxaydo tablets, a potent Schedule II narcotic prescribed for managing both acute and chronic moderate-to-severe pain. The company also offers the Nexafed line, consisting of pseudoephedrine and acetaminophen tablets, widely utilized as nasal decongestants in a range of over-the-counter and prescription formulations for cold, sinus, and allergy relief. Beyond its current offerings, Acura is actively advancing six additional opioid products through various stages of formulation development. To support its global reach, Acura Pharmaceuticals maintains strategic collaboration and licensing agreements with Egalet US, Inc. and Egalet Ltd. for the worldwide production and commercialization of its Oxaydo products. Furthermore, it has established a development and commercialization partnership with Abuse Deterrent Pharma, LLC to create LTX-03, an immediate-release tablet leveraging the proprietary LIMITx technology. Established in 1935, the company's operations are headquartered in Palatine, Illinois.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$6.60K
変化(1日)
-50.00%
変化(1年)
-80.00%
US
取引 Acura Pharmaceuticals, Inc. (ACUR)

カテゴリー

Acura Pharmaceuticals, Inc.(ACUR)の発行済株式数
August 2026 時点の発行済株式数 0
Acura Pharmaceuticals, Inc. の最新の財務報告および株価によると、現在の発行済株式数は 0 です。August 2026 の終わりには、同社は 0 株の発行済株式 を有していました。発行済株式数は、通常、株式分割や自社株買いによって影響を受けます。
Acura Pharmaceuticals, Inc.(ACUR)の発行済株式数の履歴(2026 ~ 2026)
各年末時点の発行済株式数
発行済株式数 変化
提供された日付のデータは十分ではありません。
類似企業や競合他社の発行済株式数